d-nome funding: Synthetic biology startup D-Nome raises $1.5 million in funding from Ankur Capital, Campus Fund
Synthetic biology startup D-Nome raised $1.5 million in seed funding from Ankur Capital, Campus Fund, and other investors.
D-Nome intends to democratise molecular diagnostics with their deviceless PCR tech.
“Started in July 2021 by scientists Divya Sriram and Sujoy Deb – from Telangana-based Atal Incubation Centre-The Centre of Cellular and Molecular Biology, the startup’s focus is to build rapid point-of-care diagnostics for human infectious diseases and other applications using genomics and synthetic biology.”
“Our mission is to fill the gap in testing and enable personalised medicine at scale, something that has not been successful due to the lack of scalable and accurate diagnostic tools. We hope to create significant impact socially and economically for developing nations and pave the way for next-generation healthcare relying heavily on genomics,”
Currently, there are three main methods of testing – routine culture which is time consuming and requires infrastructure, rapid antigen/ antibody tests which are quicker but lack accuracy, and PCR/ Real time PCR (RT-PCR) tests which is the gold standard for accuracy but is expensive and needs skilled labour.
Stay on top of technology and startup news that matters. Subscribe to our daily newsletter for the latest and must-read tech news, delivered straight to your inbox.
Synthetic biology startup D-Nome raised $1.5 million in seed funding from Ankur Capital, Campus Fund, and other investors.
D-Nome intends to democratise molecular diagnostics with their deviceless PCR tech.
“Started in July 2021 by scientists Divya Sriram and Sujoy Deb – from Telangana-based Atal Incubation Centre-The Centre of Cellular and Molecular Biology, the startup’s focus is to build rapid point-of-care diagnostics for human infectious diseases and other applications using genomics and synthetic biology.”
“Our mission is to fill the gap in testing and enable personalised medicine at scale, something that has not been successful due to the lack of scalable and accurate diagnostic tools. We hope to create significant impact socially and economically for developing nations and pave the way for next-generation healthcare relying heavily on genomics,”
Currently, there are three main methods of testing – routine culture which is time consuming and requires infrastructure, rapid antigen/ antibody tests which are quicker but lack accuracy, and PCR/ Real time PCR (RT-PCR) tests which is the gold standard for accuracy but is expensive and needs skilled labour.
Stay on top of technology and startup news that matters. Subscribe to our daily newsletter for the latest and must-read tech news, delivered straight to your inbox.
Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.